长期癌症监测:Forteo患者登记监测研究结果
Forteo患者登记研究旨在估计接受特立帕肽治疗的美国患者中骨肉瘤的发生率,纳入2009至2019年登记的75247例患者,累计361763人年。通过与42个州癌症登记处链接,未发现骨肉瘤病例,粗发病率为0(95%CI 0-10.2)/百万人年,标准化发病比为0(95%CI 0-3.0)。因随访时间少于预期且无病例,对骨肉瘤发生率的结论能力有限。
要点
- 特立帕肽治疗患者中未观察到骨肉瘤病例。
- 粗发病率为0(95%CI 0-10.2)/百万人年。
- 标准化发病比为0(95%CI 0-3.0)。
核心结论
- 在Forteo患者登记研究纳入的患者中未发现骨肉瘤病例,但因随访时间少于预期且无病例,对骨肉瘤发生率的结论能力有限。
研究设计与样本
- 前瞻性、自愿参与的Forteo患者登记研究,纳入2009至2019年登记的美国成年特立帕肽处方患者,每年与参与州癌症登记处链接(2010-2019)以识别骨肉瘤病例。
主要发现
- 共纳入75247例患者,累计361763人年,与42个州癌症登记处链接(覆盖93%美国人口),包含6180例骨肉瘤信息。
- 登记入组后未发现与骨肉瘤发病病例的匹配。
- 粗发病率为0(95%CI 0-10.2)/百万人年,标准化发病比为0(95%CI 0-3.0)。
局限性
- 患者随访时间少于预期且未识别出任何病例,限制了对登记患者中骨肉瘤发生率的结论能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The Forteo Patient Registry estimated the incidence of osteosarcoma in US patients treated with teriparatide and enrolled in the study between 2009 and 2019. No incident cases of osteosarcoma were identified among patients registered, and the crude incidence rate was 0 (95% confidence interval [CI], 0-10.2) cases per million person-years. PURPOSE: The prospective, voluntary Forteo Patient Registry was established to estimate the incidence of osteosarcoma in patients who have received treatment with teriparatide (Forteo). METHODS: Information on US adults prescribed teriparatide and enrolled in the Forteo Patient Registry 2009-2019 was linked with data from participating state cancer registries annually (2010-2019) to identify incident osteosarcoma cases using a standardized linkage algorithm. Teriparatide exposure was ascertained from self-reported data that included teriparatide initiation and demographics necessary to complete linkage. Osteosarcoma cases diagnosed on or after January 1, 2009, were identified by participating state cancer registries. The crude incidence rate (IR) and standardized incidence ratio (SIR) of observed cases to the expected number of cases adjusted to the background rate (3 per million person-years) and corresponding 95% CIs for the occurrence of osteosarcoma were calculated whereby the cumulative amount of person-time observed was adjusted for mortality. RESULTS: Data for 75,247 enrolled patients (representing 361,763 cumulative person-years) were linked to each of 42 participating state cancer registries (covering 93% of the US population), which included information on 6180 cases of osteosarcoma. No matches with incident cases of osteosarcoma following registry enrollment were found. The crude IR was 0 (95% CI, 0-10.2) cases per million person-years and the SIR was 0 (95% CI, 0-3.0). CONCLUSIONS: The ability to draw conclusions about the incidence of osteosarcoma among patients participating in the registry was limited due to the smaller than expected amount of patient follow-up time and the fact that no cases were identified.
引用
- Gilsenan A, Harris D, Reynolds M, et al. Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study. Osteoporos Int. 2020. PMID: 33151378. doi:10.1007/s00198-020-05718-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。